ES2099094T3 - Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos. - Google Patents

Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.

Info

Publication number
ES2099094T3
ES2099094T3 ES90901954T ES90901954T ES2099094T3 ES 2099094 T3 ES2099094 T3 ES 2099094T3 ES 90901954 T ES90901954 T ES 90901954T ES 90901954 T ES90901954 T ES 90901954T ES 2099094 T3 ES2099094 T3 ES 2099094T3
Authority
ES
Spain
Prior art keywords
treatment
methods
c2h4o
biological fluids
hydrophobic interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90901954T
Other languages
English (en)
Inventor
Robert L Hunter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2099094T3 publication Critical patent/ES2099094T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/13—Burn treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

DE ACUERDO CON EL INVENTO SE SUMINISTRA UN METODO Y COMPUESTO PARA EL TRATAMIENTO DE INTERACCIONES HIDROFOBICAS PATOLOGICAS EN FLUIDOS BIOLOGICOS EN LOS CUALES EXISTE UN DETERIORO AGUDO DE LA CIRCULACION, ESPECIALMENTE DE LA MICROCIRCULACION. MAS PARTICULARMENTE, EL INVENTO SE REFIERE A COMPUESTOS Y METODOS PARA EL TRATAMIENTO DE ENFERMEDADES CIRCULATORIAS QUE COMPRENDE EL USO DE CIERTOS COPOLIMEROS ACTIVOS SUPERFICIALES DE LA CONDENSACION DEL OXIDO DE OXIDO SOLOS COMO EN COMBINACION CON OTROS COMPUESTOS. EL COPOLIMERO ACTIVO SUPERFICIAL PUEDE SER UN PRUDUCTO DE CONDENSACION DEL OXIDO DE OXIDO RAL: HO(C2H4O)B(C3H6O)A(C2H4O)BH, EN LA QUE A ES UN ENTERO TAL QUE LA HIDROFOBA REPRESENTADA POR (C3H6O) TENGA UN PESO MOLECULAR APROXIMADAMENTE ENTRE 950 Y 4000, MAS PREFERIBLEMENTE ENTRE 1750 Y 3500; Y B ES UN ENTERO TAL QUE LA PARTE HIDROFILA REPRESENTADA POR (C2H4O) CONSTITUYA APROXIMADAMENTE ENTRE EL 50 Y 95% DEL PESO DEL COMPUESTO.
ES90901954T 1988-12-29 1989-12-28 Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos. Expired - Lifetime ES2099094T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/291,925 US4879109A (en) 1986-05-15 1988-12-29 Method for treating burns

Publications (1)

Publication Number Publication Date
ES2099094T3 true ES2099094T3 (es) 1997-05-16

Family

ID=23122462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90901954T Expired - Lifetime ES2099094T3 (es) 1988-12-29 1989-12-28 Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.

Country Status (13)

Country Link
US (1) US4879109A (es)
EP (1) EP0409940B1 (es)
JP (1) JP2554396B2 (es)
AT (1) ATE149791T1 (es)
AU (1) AU637996B2 (es)
CA (1) CA2006953C (es)
DE (1) DE68927859T2 (es)
DK (1) DK194690A (es)
ES (1) ES2099094T3 (es)
FI (1) FI904254A0 (es)
HU (1) HU205858B (es)
NO (1) NO903775L (es)
WO (1) WO1990007336A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5681576A (en) * 1988-11-16 1997-10-28 Mdv Technologies, Inc. Method and composition for post surgical adhesion reduction
US5073171A (en) * 1989-01-12 1991-12-17 Eaton John W Biocompatible materials comprising albumin-binding dyes
CA2081340A1 (en) * 1990-04-26 1991-10-27 R. Martin Emanuele Composition and method for topical treatment of damaged or diseased tissue
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
US5306501A (en) * 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5593683A (en) * 1990-05-01 1997-01-14 Mdv Technologies, Inc. Method of making thermoreversible polyoxyalkylene gels
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5847023A (en) * 1990-10-26 1998-12-08 Mdv Technologies, Inc. Thermal irreversible gel corneal contact lens formed in situ
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
ES2140408T3 (es) 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
GB9221883D0 (en) * 1992-10-19 1992-12-02 Wellcome Found Novel formulation
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5843470A (en) * 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6596401B1 (en) 1998-11-10 2003-07-22 C. R. Bard Inc. Silane copolymer compositions containing active agents
US6579539B2 (en) 1999-12-22 2003-06-17 C. R. Bard, Inc. Dual mode antimicrobial compositions
US6780648B1 (en) * 2000-09-20 2004-08-24 General Electric Company Method and system for selectively distributing luminescence material precursors
HRP20040421B1 (hr) * 2001-10-16 2013-05-31 Avanir Pharmaceuticals INHIBICIJA VIRUSA n-DOKOZANOLOM
US20040101507A1 (en) * 2002-11-27 2004-05-27 Janco Predovan Skin cream
AU2005262392A1 (en) * 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
EP1809272A4 (en) * 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
JP2010501486A (ja) * 2006-08-18 2010-01-21 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 移植用の臓器又は組織を保存及び／又は調製するための方法及び組成物
US20110212047A1 (en) * 2007-08-10 2011-09-01 Synth Rx, Inc. Polymer Therapy for the Treatment of Chronic Microvascular Diseases
KR20130097795A (ko) 2010-11-15 2013-09-03 매스트 테라퓨틱스 인코포레이티드 위태로운 조직의 산소화 증강 방법
EP3057598A1 (en) 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
JP6747748B2 (ja) 2014-07-07 2020-08-26 ライフラフト バイオサイエンシーズ，インコーポレイテッド 長期循環物質のないポロクサマー組成物、その産生方法およびその使用
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3639575A (en) * 1968-06-19 1972-02-01 Basf Wyandotte Corp Silver ion gel compositions and method of using the same
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4105650A (en) * 1975-04-11 1978-08-08 Edward Shanbrom, Inc. Method of preserving blood plasma i
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
CA1244774A (en) * 1983-11-09 1988-11-15 Thomas Jefferson University Medium for storing blood platelets
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition

Also Published As

Publication number Publication date
CA2006953C (en) 2000-10-03
NO903775D0 (no) 1990-08-28
WO1990007336A1 (en) 1990-07-12
JP2554396B2 (ja) 1996-11-13
NO903775L (no) 1990-10-22
ATE149791T1 (de) 1997-03-15
DK194690A (da) 1990-10-22
DE68927859D1 (de) 1997-04-17
HU901138D0 (en) 1991-03-28
EP0409940A1 (en) 1991-01-30
FI904254A7 (fi) 1990-08-29
JPH03505879A (ja) 1991-12-19
AU637996B2 (en) 1993-06-17
HU205858B (en) 1992-07-28
DK194690D0 (da) 1990-08-15
US4879109A (en) 1989-11-07
EP0409940B1 (en) 1997-03-12
AU4849590A (en) 1990-08-01
FI904254A0 (fi) 1990-08-29
EP0409940A4 (en) 1993-01-27
DE68927859T2 (de) 1997-08-07
CA2006953A1 (en) 1990-06-29

Similar Documents

Publication Publication Date Title
ES2099094T3 (es) Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
ES2054069T3 (es) Composicion cosmetica o farmaceutica que contiene microesferas de polimeros o de cuerpos grasos cargados de al menos un producto activo.
ES2161232T3 (es) Composiciones tensioactivas de base acuosa.
NO874150D0 (no) Preparater inneholdende propylenglykol og/eller polyetylenglykol og urinstoff som aktive hovedkomponenter og anvendelse derav.
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
MX171876B (es) Sistema de vehiculo para usarse en composiciones cosmeticas
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
ES8308698A1 (es) Procedimiento para preparar una composicion penetrable por la piel a base de agentes terapeuticos sistematicamente activos
MX9305535A (es) Composiciones y concentrados germicidas a base de yodo-detergente, acuosos y estables.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
SV2002000969A (es) Composicion parenteral reconstituible
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
PE3096A1 (es) Formulacion conteniendo selenio
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
CO5540370A2 (es) Comprimido que comprende cetirizina y pseudoefredina
ES2628707T3 (es) Composición tópica potenciada
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 409940

Country of ref document: ES